Previous studies on immunotherapy biomarkers mainly focused on PD-L1 immunohistochemistry (IHC), tumor mutation burden (TMB), and microsatellite instability-high (MSI-H) but failed to identify potential responders accurately. The gene discussed is CD274; the disease is neoplasm.